Download Bibliografía completa

320.e1
Bibliografía completa
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
frequently identified anaerobes isolated from human infections. Antimicrob Agents Chemother. 2002;46:1136-1140.
Woods GL, Bergmann JS, Witebsky FG, et al. Multisite
reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J Clin Microbiol. 1999;37:1676-1682.
Chambers HF, Turner J, Schecter GF, et al. Imipenem for
treatment of tuberculosis in mice and humans. Antimicrob
Agents Chemother. 2005;49:2816-2821.
Drusano GL . An overview of the pharmacology of
imipenem/cilastatin. J Antimicrob Chemother. 1986;18(suppl
E):79-92.
Moon YS, Chung KC, Gill MA. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Clin
Infect Dis. 1997;24(suppl 2):S249-S255.
Cirillo I, Vaccaro N, Turner K, et al. Pharmacokinetics,
safety, and tolerability of doripenem after 0.5-, 1-, and
4-hour infusions in healthy volunteers. J Clin Pharmacol.
2009;49:798-806.
Majumdar AK, Musson DG, Birk KL, et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob
Agents Chemother. 2002;46:3506-3511.
Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of
the carbapenems. Drugs. 2007;67:1027-1052.
Nicolau DP. Pharmacodynamic optimization of ␤-lactams
in the patient care setting. Crit Care. 2008;12(suppl 4):S2.
Miller AD, Ball AM, Bookstaver PB, et al. Epileptogenic
potential of carbapenem agents: mechanism of action, seizure
rates, and clinical considerations. Pharmacotherapy. 2011;31:
408-423.
Mori H, Takahashi K, Mizutani T. Interaction between valproic acid and carbapenem antibiotics. Drug Metab Rev.
2007;39:647-657.
Frumin J, Gallagher JC. Allergic cross-sensitivity between
penicillin, carbapenem, and monobactam antibiotics: what
are the chances? Ann Pharmacother. 2009;43:304-315.
Prescott Jr WA, DePestel DD, Ellis JJ, Regal RE. Incidence
of carbapenem-associated allergic-type reactions among
patients with versus patients without a reported penicillin
allergy. Clin Infect Dis. 2004;38:1102-1107.
Sodhi M, Axtell SS, Callahan J, Shekar R. Is it safe to use
carbapenems in patients with a history of allergy to penicillin? J Antimicrob Chemother. 2004;54:1155-1157.
Cunha BA, Hamid NS, Krol V, Eisenstein L. Safety of meropenem in patients reporting penicillin allergy: lack of allergic
cross reactions. J Chemother. 2008;20:233-237.
Romano A, Viola M, Gueant-Rodriguez RM, et al. Brief
communication: tolerability of meropenem in patients with
IgE-mediated hypersensitivity to penicillins. Ann Intern
Med. 2007;146:266-269.
Romano A, Viola M, Gueant-Rodriguez RM, et al. Imipenem
in patients with immediate hypersensitivity to penicillins. N
Engl J Med. 2006;354:2835-2837.
Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. Acinetobacter baumannii 2002-2008: increase of carbapenemassociated multiclass resistance in the United States. Microb
Drug Resist. 2010;16:209-215.
Rodriguez-Martinez JM, Poirel L, Nordmann P. Molecular
epidemiology and mechanisms of carbapenem resistance
in Pseudomonas aeruginosa. Antimicrob Agents Chemother.
2009;53:4783-4788.
Sykes RB, Wells JS, Parker WL, et al. Aztreonam: discovery
and development of the monobactams. N J Med. 1986;(Spec
No):8-15.
Sykes RB, Bonner DP, Bush K, Georgopapadakou NH. Azthreonam (SQ 26, 776), a synthetic monobactam specifically
active against aerobic gram-negative bacteria. Antimicrob
Agents Chemother. 1982;21:85-92.
Swabb EA. Clinical pharmacology of aztreonam in healthy
recipients and patients: a review. Rev Infect Dis. 1985;7(suppl
4):S605-S612.
Fuchs PC, Barry AL, Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from
11 North American medical centers. Antimicrob Agents
Chemother. 2001;45:1915-1918.
Stutman HR, Marks MI, Swabb EA. Single-dose pharmacokinetics of aztreonam in pediatric patients. Antimicrob
Agents Chemother. 1984;26:196-199.
Fillastre JP, Leroy A, Baudoin C, et al. Pharmacokinetics
of aztreonam in patients with chronic renal failure. Clin
Pharmacokinet. 1985;10:91-100.
Product information. Prescribing information for Azactam
(aztreonam for injection, USP). New York: Bristol-Myers
Squibb; 2010.
Patriarca G, Schiavino D, Lombardo C, et al. Tolerability of
aztreonam in patients with IgE-mediated hypersensitivity to
b-lactams. Int J Immunopathol Pharmacol. 2008;21:375-379.
Moss RB, McClelland E, Williams RR, et al. Evaluation of
the immunologic cross-reactivity of aztreonam in patients
with cystic fibrosis who are allergic to penicillin and/or
cephalosporin antibiotics. Rev Infect Dis. 1991;13(suppl 7):
S598-S607.
Parkins MD, Pitout JD, Church DL , et al. Treatment
of infections caused by metallo- ␤-lactamase-producing
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
Pseudomonas aeruginosa in the Calgary Health Region. Clin
Microbiol Infect. 2007;13:199-202.
Jones RN, Farrell DJ, Mendes RE, Sader HS. Comparative
ceftaroline activity tested against pathogens associated
with community-acquired pneumonia: results from an
international surveillance study. J Antimicrob Chemother.
2011;66(suppl 3):iii69-iii80.
Rhomberg PR, Deshpande LM, Kirby JT, Jones RN. Activity
of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program
(2006). Diagn Microbiol Infect Dis. 2007;59:425-432.
Adam HJ, DeCorby M, Rennie R, et al. Canadian Antimicrobial Resistance A. Prevalence of antimicrobial resistant
pathogens from blood cultures from Canadian hospitals:
results of the CANWARD 2007-2009 study. Diagn Microbiol
Infect Dis. 2011;69:307-313.
Zhanel GG, Adam HJ, Low DE, et al. Canadian Antimicrobial Resistance A. Antimicrobial susceptibility of
15,644 pathogens from Canadian hospitals: results of the
CANWARD 2007-2009 study. Diagn Microbiol Infect Dis.
2011;69:291-306.
Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity
of doripenem (S-4661): a global surveillance report (2003).
Clin Microbiol Infect. 2005;11:974-984.
Song JH, Ko KS, Lee MY, et al. In vitro activities of ertapenem against drug-resistant Streptococcus pneumoniae and
other respiratory pathogens from 12 Asian countries. Diagn
Microbiol Infect Dis. 2006;56:445-450.
Fritsche TR , Sader HS, Jones RN. Antimicrobial activity
of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary
pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn Microbiol Infect Dis.
2008;61:86-95.
Reynolds R, Potz N, Colman M, et al. Surveillance BEWPoBR. Antimicrobial susceptibility of the pathogens of
bacteraemia in the UK and Ireland 2001-2002: the BSAC
Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother. 2004;53:1018-1032.
Luna VA, King DS, Gulledge J, et al. Susceptibility of Bacillus
anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and Bacillus thuringiensis to 24 antimicrobials
using Sensititre automated microbroth dilution and Etest
agar gradient diffusion methods. J Antimicrob Chemother.
2007;60:555-567.
Cavallo JD, Ramisse F, Girardet M, et al. Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in
France between 1994 and 2000. Antimicrob Agents Chemother. 2002;46:2307-2309.
Marco F, Almela M, Nolla-Salas J, et al. In vitro activities
of 22 antimicrobial agents against Listeria monocytogenes
strains isolated in Barcelona, Spain. The Collaborative Study
Group of Listeriosis of Barcelona. Diagn Microbiol Infect Dis.
2000;38:259-261.
Rolston KV, LeBlanc BM, Streeter H, Ho DH. In vitro activity
of ertapenem against bacterial isolates from cancer patients.
Diagn Microbiol Infect Dis. 2002;43:219-223.
Norskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators
against bacterial isolates collected as part of the TEST study
in Europe (2004-2007). Int J Antimicrob Agents. 2009;34:
121-130.
Zhanel GG, Simor AE, Vercaigne L, Mandell L, Canadian
Carbapenem Discussion G. Imipenem and meropenem:
comparison of in vitro activity, pharmacokinetics, clinical
trials and adverse effects. Can J Infect Dis. 1998;9:215-228.
Nishino T, Otsuki M, Izawa M. In vitro and in vivo antibacterial activity of doripenem. Jpn J Chemother [Japanese].
2005;53(S1):32-46.
Livermore DM, Carter MW, Bagel S, et al. In vitro activities
of ertapenem (MK-0826) against recent clinical bacteria
collected in Europe and Australia. Antimicrob Agents Chemother. 2001;45:1860-1867.
Turner PJ. Meropenem activity against European isolates:
report on the MYSTIC (Meropenem Yearly Susceptibility
Test Information Collection) 2006 results. Diagn Microbiol
Infect Dis. 2008;60:185-192.
Jean SS, Hsueh PR , Lee WS, et al. Carbapenem susceptibilities and non-susceptibility concordance to different
carbapenems amongst clinically important Gram-negative
bacteria isolated from intensive care units in Taiwan: results
from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009. Int J Antimicrob Agents.
2013;41:457-462.
Jones RN, Kirby JT, Rhomberg PR. Comparative activity of
meropenem in US medical centers (2007): initiating the 2nd
decade of MYSTIC program surveillance. Diagn Microbiol
Infect Dis. 2008;61:203-213.
Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among gram-negative bacilli isolated
from Latin America: results from SENTRY Antimicrobial
Surveillance Program (Latin America, 2008-2010). Diagn
Microbiol Infect Dis. 2012;73:354-360.
Snydman DR, Jacobus NV, McDermott LA. In vitro activities
of doripenem, a new broad-spectrum carbapenem, against
Capítulo 22 Otros antibióticos β-lactámicos
1. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-␤lactamases: the quiet before the storm?. Clin Microbiol Rev.
2005;18:306-325.
2. Nordmann P, Naas T, Poirel L . Global spread of
carbapenemase-producing Enterobacteriaceae. Emerg Infect
Dis. 2011;17:1791-1798.
3. Trias J, Nikaido H. Outer membrane protein D2 catalyzes
facilitated diffusion of carbapenems and penems through
the outer membrane of Pseudomonas aeruginosa. Antimicrob
Agents Chemother. 1990;34:52-57.
4. Satake S , Yoshihara E , Nakae T. Diffusion of ␤ -lactam
antibiotics through liposome membranes reconstituted
from purified porins of the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1990;34:
685-690.
5. Davies TA, Marie Queenan A, Morrow BJ, et al. Longitudinal
survey of carbapenem resistance and resistance mechanisms
in Enterobacteriaceae and non-fermenters from the USA in
2007-09. J Antimicrob Chemother. 2011;66:2298-2307.
6. Livermore DM. Interplay of impermeability and chromosomal ␤-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1992;36:
2046-2048.
7. Yigit H, Anderson GJ, Biddle JW, et al. Carbapenem resistance in a clinical isolate of Enterobacter aerogenes is associated with decreased expression of OmpF and OmpC porin
analogs. Antimicrob Agents Chemother. 2002;46:3817-3822.
8. Doumith M, Ellington MJ, Livermore DM, Woodford N.
Molecular mechanisms disrupting porin expression in
ertapenem-resistant Klebsiella and Enterobacter spp. clinical
isolates from the UK. J Antimicrob Chemother. 2009;63:
659-667.
9. Martinez-Martinez L, Pascual A, Hernandez-Alles S, et al.
Roles of ␤-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae.
Antimicrob Agents Chemother. 1999;43:1669-1673.
10. Kohler T, Michea-Hamzehpour M, Epp SF, Pechere JC.
Carbapenem activities against Pseudomonas aeruginosa:
respective contributions of OprD and efflux systems. Antimicrob Agents Chemother. 1999;43:424-427.
11. Masuda N, Sakagawa E, Ohya S, et al. Substrate specificities
of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux
pumps in Pseudomonas aeruginosa . Antimicrob Agents
Chemother. 2000;44:3322-3327.
12. Fuda C, Suvorov M, Vakulenko SB, Mobashery S. The basis
for resistance to ␤-lactam antibiotics by penicillin-binding
protein 2a of methicillin-resistant Staphylococcus aureus. J
Biol Chem. 2004;279:40802-40806.
13. Hujer AM, Kania M, Gerken T, et al. Structure-activity
relationships of different ␤-lactam antibiotics against a
soluble form of Enterococcus faecium PBP5, a type II bacterial transpeptidase. Antimicrob Agents Chemother. 2005;49:
612-618.
14. Hidron AI, Edwards JR, Patel J, et al. National Healthcare
Safety Network T, Participating National Healthcare Safety
Network F. NHSN annual update: antimicrobial-resistant
pathogens associated with healthcare-associated infections:
annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control
and Prevention, 2006-2007. Infect Control Hosp Epidemiol.
2008;29:996-1011.
15. Sievert DM, Ricks P, Edwards JR , et al. National Healthcare Safety Network T. Antimicrobial-resistant pathogens
associated with healthcare-associated infections: summary
of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention,
2009-2010. Infect Control Hosp Epidemiol. 2013;34:1-14.
16. Cockerill III FR. Performance standards for antimicrobial
susceptibility testing; Twenty-first informational supplement.
Wayne, PA: Clinical and Laboratory Standards Institute;
2011.
17. Fritsche TR , Sader HS, Stillwell MG, Jones RN. Antimicrobial activity of doripenem tested against prevalent
gram-positive pathogens: results from a global surveillance
study (2003-2007). Diagn Microbiol Infect Dis. 2009;63:
440-446.
18. Jones RN, Bell JM, Sader HS, et al. In vitro potency of doripenem tested against an international collection of rarely
isolated bacterial pathogens. Diagn Microbiol Infect Dis.
2009;63:434-439.
19. Unemo M, Golparian D, Limnios A, et al. In vitro activity of
ertapenem versus ceftriaxone against Neisseria gonorrhoeae
isolates with highly diverse ceftriaxone MIC values and
effects of ceftriaxone resistance determinants: ertapenem
for treatment of gonorrhea?. Antimicrob Agents Chemother.
2012;56:3603-3609.
20. Cercenado E , Marin M , Sanchez-Martinez M , et al. In
vitro activities of tigecycline and eight other antimicrobials
against different Nocardia species identified by molecular methods . Antimicrob Agents Chemother . 2007 ; 51 :
1102-1104.
21. Goldstein EJ, Citron DM, Merriam CV, et al. Comparative
in vitro activities of ertapenem (MK-0826) against 469 less
ISBN: 978-84-9022-917-0; PII: B978-84-9022-917-0.00022-6; Autor: BENNETTSPAIN; Documento ID: 00022; Capítulo ID: c0110
C0110.indd 320.e1
12/03/15 9:05 AM
Parte I Principios básicos en el diagnóstico y el tratamiento de las enfermedades infecciosas
320.e2
recently collected clinical anaerobic isolates, with emphasis
on the Bacteroides fragilis group. Antimicrob Agents Chemother. 2008;52:4492-4496.
71. Wexler HM, Engel AE, Glass D, Li C. In vitro activities of
doripenem and comparator agents against 364 anaerobic
clinical isolates. Antimicrob Agents Chemother. 2005;49:
4413-4417.
72. Hoellman DB, Kelly LM, Jacobs MR, Appelbaum PC. In vitro
anti-anaerobic activity of the cephalosporin derivative RWJ
54428, compared to seven other compounds. Clin Microbiol
Infect. 2002;8:814-822.
73. Chin NX , Neu HC . Tigemonam, an oral monobactam .
Antimicrob Agents Chemother. 1988;32:84-91.
74. Moran JS, Levine WC. Drugs of choice for the treatment
of uncomplicated gonococcal infections. Clin Infect Dis.
1995;20(suppl 1):S47-S65.
75. Barry AL, Thornsberry C, Jones RN, Gavan TL. Aztreonam:
antibacterial activity, ␤-lactamase stability, and interpretive
standards and quality control guidelines for disk-diffusion
susceptibility tests . Rev Infect Dis . 1985 ; 7 ( suppl 4 ) :
S594-S604.
76. Sader HS, Fritsche TR, Jones RN. Potency and spectrum
trends for cefepime tested against 65746 clinical bacterial
isolates collected in North American medical centers:
results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Diagn Microbiol Infect Dis . 2005;52:
265-273.
ISBN: 978-84-9022-917-0; PII: B978-84-9022-917-0.00022-6; Autor: BENNETTSPAIN; Documento ID: 00022; Capítulo ID: c0110
C0110.indd 320.e2
12/03/15 9:05 AM